NASDAQ · PROG
Healthcare · Biotechnology
$0.88
Down-$0.03 (-3.47%)
Updated Sep 16, 2026, 8:20 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PROG does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PROG.
PROG research
Company profile and research snapshot.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2021 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2021 | Raymond James | Market Perform | — |
| Jun 3, 2021 | Baird | Neutral | — |
| May 17, 2021 | Wells Fargo | Underweight | — |
| May 14, 2021 | Raymond James | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 5, 2022
Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy
GlobeNewswire Inc. · Apr 25, 2022
Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms
GlobeNewswire Inc. · Mar 28, 2022
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs
GlobeNewswire Inc. · Mar 16, 2022
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PROG.
No results
No recent SID articles mention PROG.
